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Background: There are several challenges associated with trabeculectomy and 
medical management in Nigeria. This makes laser trabeculoplasty a viable option 
in glaucoma management. This study compares Selective Laser Trabeculoplasty 
(SLT) with Argon Laser Trabeculoplasty (ALT) in Nigerians with open angle 
glaucoma. 
Methods: This was a retrospective study performed on 26 eyes of 26 patients who 
had ALT and were recruited consecutively at the glaucoma clinic of the University 
College Hospital (UCH), and 25 eyes of 25 patients who had SLT recruited from the 
Guinness Eye Centre, Lagos University Teaching Hospital, Lagos (LUTH). The main 
outcome measure was intraocular pressure (IOP) at one month, three months, six 
months and one year. Success was defined as IOP reduction of 3mmHg or more 
without additional intervention (glaucoma surgery) from the pretreatment IOP. 
Results: The mean age of the patients who had ALT was 58.0±7.1 years (range of 
40.0-70.0 years) while the mean age of patients who had SLT was 53.52 ± 14.65 
years (Range 22 – 74 years). There was no statistically significant difference in IOP 
between the two groups at the different time periods. Based on our criterion for 
success, 84.5% of the patients had successful outcome at six months in the ALT 
group while 70.5% were successful in the SLT group (P=0.6). At one year, there was 
no statistically significant difference between the two groups on log rank 
test/Mantel Cox (Chi square 3.36, df=1, P=0.07.) 
Conclusion: This study highlights the efficacy and safety of both lasers in Nigerians 
and adds to knowledge that the adjunctive IOP reducing effect of both lasers is 




Glaucoma is a huge problem in Sub-Saharan Africa (SSA) and in Nigeria. It affects 
Africans on a scale unparalleled in most of the world. Africa is disproportionately 
affected by blindness with glaucoma accounting for 15% of blindness compared to 8% 
in the world.1 Reported prevalence of glaucoma in population based studies within SSA 
ranges from 5.3% among South African blacks,2 to as high as 6.9% in Nigeria3  
 
Despite this high prevalence in Nigeria there is limited glaucoma-specific health care 
resource availability. Medical management of glaucoma is impractical and rarely 
successful in Nigeria. The high cost of anti-glaucoma medications, the need for regular 
follow up, and unavailability of the drugs worsens compliance which is an important 
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factor in delaying progression in glaucoma management 4. In Nigeria, trabeculectomy is 
the standard method of surgical treatment and has been recommended as the primary 
treatment for glaucoma in Africans.4 Intra-operative anti-fibrotics such as 5 fluorouracil 
or mitomycin C have been shown to safely increase the rate of success of primary 
trabeculectomy for open angle glaucoma.5,6 Despite its success however, it is generally 
not accepted by many patients and therefore it is not performed in large numbers. 
Reports from Nigeria have shown acceptability to be as low as 8.2%.7 One major reason 
for this is the uncertain results post trabeculectomy with some patients loosing vision at 
least temporarily and cataracts becoming worse with up to 29% requiring cataract 
surgery 5 years postoperatively.8 
 
The challenges associated with trabeculectomy and medical management in Nigeria 
makes laser trabeculoplasty a viable option in glaucoma management. Argon laser 
trabeculoplasty enhances the outflow aqueous humor and has been in use for the 
management of glaucoma since 1979. Two main theories have been proposed to explain 
its mechanism of action. The mechanical theory proposes that coagulative damage to 
the trabecular meshwork (TM) results in collagen shrinkage and subsequent tightening 
of the meshwork in the area of each burn and reopening of the adjacent untreated inter-
trabecular spaces9 while the cellular theory proposes a cellular activation of the TM 
with increased cell replication thereby increasing the number of cells involved in 
maintaining the TM outflow.10,11  
 
Selective trabeculoplasty on the other hand was introduced by Latina and Park and 
gained FDA approval in 2001.12,13 It uses a Q switched, 3 nanosecond, frequency 
doubled, neodymium yttrium aluminium garnet laser (Nd:YAG laser); 532nm 
wavelength green laser to selectively target the pigment granules in the trabecular 
meshwork cells. This results in the release of cytokines which bind with the Schlemm’s 
canal endothelial cells, compromising the barrier, increasing aqueous outflow and thus 
causing a reduction in intraocular pressure (IOP). One major advantage of SLT over ALT 
is the minimal thermal damage and its repeatability. The argon laser machine on the 
other hand is cheaper and can be used to treat other ocular diseases. This is an 
important consideration in resource constrained environment such as Nigeria.  
 
Although several studies done among the Caucasians have shown that ALT and SLT 
have similar efficacy in terms of IOP lowering,14-17 there is yet no such comparative 
study done in Nigeria. The objective of this study was to compare SLT and ALT in terms 
of IOP lowering in Nigerians with open angle glaucoma.   
 
Patients and Methods 
 
This was a retrospective study performed on 26 eyes of 26 patients who had ALT and 
were recruited consecutively at the glaucoma clinic of the University College Hospital, 
and 25 eyes of 25 patients who had SLT recruited from the Guinness Eye Centre, Lagos 
University Teaching Hospital, Lagos The inclusion criteria for the procedure were 
patients with primary open angle glaucoma who had uncontrolled or suboptimal IOP 
control and/or had progressive visual field defects on automated standard Humphreys 
visual field machine. All patients were on at least one anti-glaucoma medication 
(prostaglandin analogue) and were followed up for a minimum of one year. The study 
complied with the declaration of Helsinki.  
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Information recorded included the age, sex, number of pre-operative medications, class 
of preoperative medications and preoperative (baseline) intraocular pressure. Each 
patient had either selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty 
(ALT) done as an adjunctive treatment.  
 
The SLT protocol consisted of 100 applications in 360o of the anterior chamber angle 
with 25 spots per quadrant and energy level of 0.8 – 1.2 mj delivered to the junction 
between the non pigmented and pigmented part of the trabecular meshwork with the 
use of a Latina SLT Gonio Laser lens. Patients were pre treated with a drop of Gutt 
Brimonidine (Alphagan®) 0.2%. One hour after pretreatment with 0.2% brimonidine, a 
drop of topical anaesthetic agent (tetracaine) was applied to the eye to be treated before 
the application of the laser.  
 
All patients were treated by the same Ophthalmologist (O.A).  Intraocular pressure 
measurement was done 1 hour postoperatively in all patients, any spike in IOP was 
treated with a drop of Gutt Brimonidine 0.2%.  Patients were placed on Gutt Diclofenac 
(Voltaren ophtha®) 8 hourly for 3 days post SLT.   
 
The ALT protocol consisted of 50 applications of 50 micrometer spot sized burns of 0.1s 
delivered to the junction between the non pigmented and pigmented part of the 
trabecular meshwork with the use of a laser antireflective coated Goldmann two mirror 
lens (Ocular Instruments, Bellevue, WA, USA). Only 180 degrees of the anterior chamber 
angle was treated at a sitting with approximately 25 burn applications delivered to each 
quadrant. Laser power was adjusted between 400 and 1,200mw to produce tiny 
champagne bubbles. Patients were thereafter placed on gutt diclofenac (Voltaren 
Ophtha) 6 hourly for one week. All patients were treated by the same surgeon (O.O). All 
patients were pretreated with one drop of Gutt Brimonidine 0.2% (Alphagan). One hour 
after pretreatment with 0.2% brimonidine, a drop of topical anaesthetic agent 
(tetracaine) was applied to the eye to be treated before the application of the laser. All 
patients were directed to continue with the antiglaucoma medications they were pre 
laser treatment. 
 
Patients were evaluated at one month, three months, six months and one year. At each 
visit, anterior segment examination, visual acuity and IOP measurements were 
performed. IOP was measured with the Goldmann applanation tonometer between 
9.00am and 12 noon to minimize the effect of diurnal variations. The mean of 2 readings 
at each visit was recorded. Our criterion for defining successful outcome was based on 
an earlier study.16 This was defined as IOP reduction of 3mmhg or more without 
additional intervention (glaucoma surgery) from the pretreatment IOP. All statistical 
analysis was performed using SPSS software 18.0 (SPSS, Inc, Chicago, Illinois, USA). 




A total of 26 eyes of 26 patients were treated during this period with ALT while 25 eyes 
of 25 patients had SLT. The mean age of the patients who had ALT was 58.0±7.1 years 
(range of 40.0-70.0 years) while the mean age of patients who had SLT                            
was 53.52 ± 14.65 years (Range 22 – 74 years). Table 1 show the demographic and 
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baseline characteristics of the patients.  There was no statistically significant difference 
in the demographic characteristics of the patients. There were 10 males (38.5%) and 16 
females (61.5%) in the ALT group while there were 16 males (64.0%) and 9 females 
(36.0%) in the SLT group.  
 
Twenty three patients had a minimum follow up of one year (88.5%) in the ALT group 
and three patients were lost to follow up. In the SLT group however, about half of the 
patients (50%) were lost to follow up at one year.  
 
Table 1. Demographic characteristics of patients 
Demographic characterisitics Patients who had 
ALT 
Patients who had 
SLT 
P value 
Age (SD) (years) 58.0(7.1) 53.5 (14.65) P=0.28 
Sex: 
Male (%) 










 POAG (%) 

























All the patients in both groups were on medical therapy for glaucoma and all the 
patients had open angle glaucoma with Shaffers grade ≥3 on gonioscopy. Most of the 
patients (61.6%) were on ≥2 different anti-glaucoma medications. The mean eye drop 
use was 2.8± 0.9 in the ALT group and 2.04±0.73 in the SLT group and this was 
statistically significant (P<0.01) with the patients on ALT being on more eye-drops than 
patients in the SLT group.  
 
Changes in Intraocular Pressure  
The mean IOP at baseline (prior to treatment) was 19.8±3.1mmhg (range of 16.0-
26.0mmhg) in the group that had ALT and 19.0±6.7mmhg (range of 10-32mmhg) in the 
SLT group.  The mean IOP was higher in the ALT group compared with the SLT group. In 
the ALT group there was no patient with a baseline IOP of ≤15mmhg while in the SLT 
group 9 patients (36%) had IOP ≤ 15mmhg. The mean IOP in these nine patients was 
11.8mmhg. The mean IOP one month after ALT was 15.7±3.2mmhg and 14.0±2.9 in the 
SLT group. Table 2 compares the mean IOP in both groups with time.  There was no 
statistically significant difference between the two groups at the different time periods. 
 
Fig 1 shows the IOP reductions in both groups at one month, three months and six 
months. Based on our criterion for success 84.5% of the patients had successful 
outcome at six months in the ALT group while 70.5% were successful in the SLT group 
(P=0.6). Fig 2 shows the survival curve of the patients based on the criterion for success 
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at one year. There was no statistically significant difference between the two groups on 
log rank test/Mantel Cox (Chi square 3.36, df=1, P=0.07.) 
 
Table 2. Comparison of the mean pretreatment IOP with mean IOP drop based on time 
 






P - Value 
Mean IOP Pre-treatment 19.8±3.1 19.0±6.7 0.68 
Mean IOP at one month  15.7±3.2 14.0±2.9 0.07 
Mean IOP at 3 months 15.8±2.5 16.5±7.2 0.59 
Mean IOP at six months 14.7±2.8 15.9±0.8 0.73 
Mean IOP Drop at one month 5.0±3.5 5.3±5.0 0.94 
Mean IOP drop at three months 4.4±3.6 3.3±6.5 0.70 
Mean IOP drop at six months 5.2±1.8 5.0±4.61 0.93 
Mean % IOP drop at one month 23.7±17.5 21.8±22.8 0.49 
Mean %IOP drop at three months 20.4±17.2 15.8±2.5 0.88 
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Figure 2. Kaplan Meier survival curve showing survival functions of  
SLT and ALT at one year 
Discussion   
 
Both ALT and SLT have been used successfully in the treatment of POAG. Several studies 
have documented the efficacy of these 2 laser treatments in reducing IOP 15-17. In this 
study we compared the IOP lowering efficacy of ALT with SLT in a retrospective study 
over 6 months and reported the treatment survival at one year. There was no 
statistically significant difference in the mean IOP between the two groups. To the best 
of our knowledge this is the first study from West Africa to compare ALT and SLT 
treatment outcomes. 
 
Several studies have been done in other populations to compare the 2 laser treatment 
modalities. A few of these studies have been non randomized studies and they all 
reported that SLT and ALT were similar in IOP reduction, biological effects, and 
complication rates among the patients studied.14,16,18 Other randomized studies have 
also reported the same finding. Damji et al17 in a randomized clinical trial compared the 
effect of SLT and ALT over a period of 18 months and found similar IOP lowering effect 
in both groups. In another study by Juzych et al19 in which 195 patients with POAG were 
treated with SLT or ALT, they reported that the IOP lowering effect of both treatments 
were similar. In a similar study Popiela et al20 treated 27 patients with ALT in one eye 
                  
                                 ALT 
 
                                 
 
                                       SLT   
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and SLT in the other eye and they also reported similar results with no statistically 
significant difference in the intraocular pressure in both eyes.  
 
Our results show that more patients were successful in the ALT group than in the SLT 
group based on the criterion for success at six months although this was not statistically 
significant. One explanation for this may the lower baseline IOP in the SLT group 
compared to the ALT group. Higher baseline IOP has been shown to have higher IOP 
reduction. 21, 22, 23 
 
There was a greater initial IOP reduction in the cohort of patients who had SLT 
compared with those who had ALT with the SLT group having a lower mean IOP at one 
month post treatment. In the ALT group however the mean IOP was lowest at 6 months 
post-treatment. Almeida et al24 compared the magnitude of IOP reduction at different 
time points following both SLT and ALT and reported that there was a significantly 
lower initial IOP drop in the SLT group compared to the ALT group. 
 
An explanation for this difference may be related to the different specific actions of the 
two lasers on the trabecular meshwork. While SLT stimulates aqueous outflow without 
structural damage to the TM, ALT causes structural damage and subsequent tissue 
healing to increase outflow facility. It is possible that this process may take a longer 
period to occur.  SLT may be a better option in patients requiring a faster IOP reduction 
compared with ALT.  Another advantage of SLT is that it uses a lower power setting 
resulting in less tissue damage to the trabecular meshwork and this allows the 
procedure to be repeatable unlike ALT.  
 
There was no major complication in the 2 groups post treatment although we could not 
assess for other secondary outcomes such as pain and inflammation between the 2 
groups since this was a retrospective study. Other limitations to this study include the 
small sample size and the short follow up period. This was not a prospective 
randomized study therefore there could be selection bias. The procedure was also 
performed on patients who were already on medications for varying lengths of time. It 
is possible that the IOP lowering effect may be different in newly diagnosed patients 
who have never used any medication.  
 
The results of our study however highlights the efficacy and safety of both lasers in 
Nigerians and adds to knowledge that the adjunctive IOP reducing effect of both lasers 
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